Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company’s ...
VANCOUVER, BRITISH COLUMBIA, CANADA, May 14, 2026 / EINPresswire.com / — Renaissance BioScience Corp., a global leader in bioengineered yeast, today announced the filing of a provisional patent ...
Univeristy of Nebraska-Lincoln (UNL) scientist Ana Maria Vélez is pioneering a genetic treatment to contain western corn rootworm. The research seeks to contain agricultural pests by targeting ...
It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...
Researchers from A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new method to study individual RNA ...
Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...
Invitrogen Corporation has announced the release of its Stealth™ RNAi Human Kinase Collection. This collection marks Invitrogen's entry into the siRNA collections market and the initiation of efforts ...
When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...
LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results